GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoviva Inc (NAS:INVA) » Definitions » Earnings per Share (Diluted)

Innoviva (Innoviva) Earnings per Share (Diluted) : $2.22 (TTM As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Innoviva Earnings per Share (Diluted)?

Innoviva's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $0.46. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $2.22.

Innoviva's EPS (Basic) for the three months ended in Mar. 2024 was $0.58. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $2.83.

Innoviva's EPS without NRI for the three months ended in Mar. 2024 was $0.59. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $2.23.

During the past 3 years, the average EPS without NRIGrowth Rate was 1.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was -17.70% per year.

During the past 13 years, Innoviva's highest 3-Year average EPS without NRI Growth Rate was 50.20% per year. The lowest was -39.40% per year. And the median was 22.20% per year.


Innoviva Earnings per Share (Diluted) Historical Data

The historical data trend for Innoviva's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoviva Earnings per Share (Diluted) Chart

Innoviva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.43 2.02 2.87 2.37 2.20

Innoviva Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.02 0.98 0.76 0.46

Competitive Comparison of Innoviva's Earnings per Share (Diluted)

For the Biotechnology subindustry, Innoviva's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoviva's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoviva's PE Ratio distribution charts can be found below:

* The bar in red indicates where Innoviva's PE Ratio falls into.



Innoviva Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Innoviva's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(179.722-0)/86.876
=2.07

Innoviva's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(36.532-0)/84.531
=0.43

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Innoviva  (NAS:INVA) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Innoviva Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Innoviva's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Innoviva (Innoviva) Business Description

Industry
Traded in Other Exchanges
Address
1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.
Executives
Marianne Zhen officer: Chief Accounting Officer C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Stephen Basso officer: Chief Financial Officer C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Margaret Koziel officer: Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alexander J Denner 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Deborah Birx director 3300 LOWELL STREET NW, WASHINGTON DC 20008
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Pavel Raifeld officer: Chief Executive Officer 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Sapna Srivastava director C/O MYOS CORPORATION, 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Larry G. Edwards officer: CEO of La Jolla Pharmaceutical C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511